156 related articles for article (PubMed ID: 38590407)
1. Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitor.
Lin PT; Hsu YC; Kao YT; Teng W; Hsieh YC; Chen WT; Su CW; Wang CT; Chai PM; Lin CC; Lin CY; Lin SM
Am J Cancer Res; 2024; 14(3):1306-1315. PubMed ID: 38590407
[TBL] [Abstract][Full Text] [Related]
2. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.
Zhao J; Guo Y; Feng T; Rong D; Kong X; Huang T; Lopez-Lopez V; Yarmohammadi H; Sakamoto Y; Zhu D; Yao A; Xia Y
J Gastrointest Oncol; 2023 Dec; 14(6):2549-2558. PubMed ID: 38196523
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a two-center study in China.
Ren SH; Cui ZL; Lang MR; Li Q; Zhang W; Fang F; Wu Q; Cui YL; Li HK; Chen P; Zhang Y; Song T
J Gastrointest Oncol; 2022 Jun; 13(3):1266-1277. PubMed ID: 35837206
[TBL] [Abstract][Full Text] [Related]
5. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
Hong YM; Yoon KT; Cho M
BMC Cancer; 2021 May; 21(1):569. PubMed ID: 34006248
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Yang X; Deng H; Sun Y; Zhang Y; Lu Y; Xu G; Huang X
J Hepatocell Carcinoma; 2023; 10():303-313. PubMed ID: 36874252
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study.
Qiao L; He W; Wang G; Chen H; Huang F; Zhang B; Qiu Y; Liu S; Huang Z; Yuan Y; Qiu J; Yuan Y; Li B
Cancer Med; 2024 May; 13(9):e7236. PubMed ID: 38716585
[TBL] [Abstract][Full Text] [Related]
8. A multi-center retrospective study on the efficacy and safety of regorafenib
Yan T; Huang C; Peng C; Duan X; Ji D; Duan Y; Zhang W; Zhao H; Gao K; Yang X; Zhang L; Cheng J; de Castria TB; Pocha C; Tsilimigras DI; Wu T; Su G; Li Y; Yu L; Lu Y
Ann Transl Med; 2023 Jan; 11(2):109. PubMed ID: 36819518
[TBL] [Abstract][Full Text] [Related]
9. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing.
Köstek O; Demirel A; Hacıoğlu MB; Tastekin D; Karabulut S; Gündogdu A; Sever N; Ayhan M; Çelebi A; Majidova N; Yaşar A; Ağyol Y; Erel P; Kocaaslan E; Güren AK; Arıkan R; Isık S; Ercelep O; Goksu SS; Alandag C; Bilgetekin İ; Caner B; Sahin AB; Gulmez A; Akagunduz B; Kose F; Kaplan MA; Dogan E; Sakalar T; Guven DC; Gurbuz M; Ergun Y; Karaagac M; Turker S; Ozkul O; Yıldız B; Sahin S; Demiray AG; Sari M; Erdogan B; Hacıbekiroglu İ; Çakmak Öksüzoğlu ÖB; Kilickap S; Bilici A; Bayoglu İV; Topaloglu S; Cicin İ
J Chemother; 2024 Jan; ():1-9. PubMed ID: 38263804
[TBL] [Abstract][Full Text] [Related]
10. On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma.
Wang HW; Chuang PH; Su WP; Kao JT; Hsu WF; Lin CC; Huang GT; Lin JT; Lai HC; Peng CY
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359658
[TBL] [Abstract][Full Text] [Related]
11. Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting.
Falette-Puisieux M; Nault JC; Bouattour M; Lequoy M; Amaddeo G; Decaens T; Di Fiore F; Manfredi S; Merle P; Baron A; Locher C; Pellat A; Coriat R
Ther Adv Med Oncol; 2023; 15():17588359231189425. PubMed ID: 37547443
[TBL] [Abstract][Full Text] [Related]
12. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis.
Yang XG; Sun YY; Wang HQ; Li DS; Xu GH; Huang XQ
Front Oncol; 2022; 12():914385. PubMed ID: 36176392
[TBL] [Abstract][Full Text] [Related]
14. Alpha-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving immune checkpoint inhibitors with or without tyrosine kinase inhibitors or locoregional therapies.
Hsu WF; Wang HW; Chen CK; Lai HC; Chuang PH; Tsai MH; Su WP; Chen HY; Chu CS; Chou JW; Chen SH; Tsai TY; Hsiao WD; Lin CC; Huang GT; Lin JT; Peng CY
Am J Cancer Res; 2021; 11(12):6173-6187. PubMed ID: 35018250
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
Casadei-Gardini A; Rimassa L; Rimini M; Yoo C; Ryoo BY; Lonardi S; Masi G; Kim HD; Vivaldi C; Ryu MH; Rizzato MD; Salani F; Bang Y; Pellino A; Catanese S; Burgio V; Cascinu S; Cucchetti A
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3665-3671. PubMed ID: 33745079
[TBL] [Abstract][Full Text] [Related]
16. Determinants of Survival and Post-Progression Outcomes by Sorafenib-Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma.
Lee IC; Chao Y; Lee PC; Chen SC; Chi CT; Wu CJ; Wu KC; Hou MC; Huang YH
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454919
[TBL] [Abstract][Full Text] [Related]
17. Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma.
Hou JY; Xiao YT; Huang JB; Jiang XH; Jiang K; Li X; Xu L; Chen MS
Front Pharmacol; 2022; 13():917384. PubMed ID: 35734398
[No Abstract] [Full Text] [Related]
18. Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels.
Hsu PY; Cheng TS; Chuang SC; Chang WT; Liang PC; Hsu CT; Wei YJ; Jang TY; Yeh ML; Huang CI; Lin YH; Wang CW; Hsieh MY; Hou NJ; Hsieh MH; Tsai YS; Ko YM; Lin CC; Chen KY; Dai CY; Lin ZY; Chen SC; Huang JF; Chuang WL; Huang CF; Yu ML
Cancer Med; 2022 Jan; 11(1):104-116. PubMed ID: 34786871
[TBL] [Abstract][Full Text] [Related]
19. Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience.
Rimini M; Yoo C; Lonardi S; Masi G; Granito A; Bang Y; Rizzato MD; Vivaldi C; Ielasi L; Kim HD; Bergamo F; Salani F; Leoni S; Ryoo BY; Ryoo MH; Burgio V; Cascinu S; Casadei-Gardini A
Target Oncol; 2021 Sep; 16(5):653-661. PubMed ID: 34491510
[TBL] [Abstract][Full Text] [Related]
20. Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma.
Choi WM; Choi J; Lee D; Shim JH; Lim YS; Lee HC; Chung YH; Lee YS; Park SR; Ryu MH; Ryoo BY; Lee SJ; Kim KM
Hepatol Commun; 2020 Jul; 4(7):1073-1086. PubMed ID: 32626838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
